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Abstract
Background: Hypothyroidism is a common condition, particularly in the older population. Thyroid hormone
requirements change with age and serum TSH levels also alter, especially in older patients. However, in practice
laboratory reference ranges for thyroid function are not age-specific and treatment in older patients aims to
achieve a similar target thyroid function level as younger age groups.
Methods: A dual centre, single blind, randomised controlled trial was conducted to determine the feasibility of a
future definitive RCT in hypothyroid individuals aged 80 years or older who were treated with levothyroxine.
Potential participants were identified from 17 research-active GP practices (n = 377), by opportunistic invitations
(n = 9) or in response to publicity (n = 4). Participants were randomly allocated to either usual (0.4–4.0 mU/L) or a
higher (4.1–8.0 mU/L) target serum TSH range. Information on participants’ willingness to enter the trial,
acceptability of study design, length of time to complete recruitment and dose titration strategy was collected.
Results: Fifteen percent (57/390) of potentially eligible hypothyroid individuals consented to participate in this trial and
48 were randomised to trial medication for 24 weeks, giving a recruitment rate of 12 %. Recruitment averaged 5.5
participants per month over approximately 9 months. Eight participants withdrew (3/24 and 5/24 in the usual and higher
TSH arms, respectively) with the commonest reason cited (5 patients) being tiredness. Interestingly, 3/5 participants
withdrew from the site that required a visit to a Research Facility whereas only 5/43 participants withdrew from the site
that offered home visits. In the higher TSH arm, of those participants who completed the study, approximately half of
participants (10/19) reached target TSH.
Conclusions: It is feasible to perform a randomised controlled trial of thyroid hormones in hypothyroid patients aged 80
or older. A definitive trial would require collaboration with a large number of General Practices and the provision of home
visits to achieve recruitment to time and target. Power calculations should take into account that approximately 12 % of
those approached will be randomised and 1 in 6 participants are likely to withdraw from the study. Finally, several dose
adjustments may be required to achieve target serum TSH levels in this age group.
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Background
Thyroid hormones regulate metabolism and impact on
several organs in the body. Hypothyroidism (underactive
thyroid) is a common endocrine condition in which the
thyroid gland produces insufficient thyroid hormones.
Hypothyroidism is more prevalent in women and in
older individuals with rates of up to 16 % reported in
those aged over 80 years [1, 2]. Hypothyroidism is diag-
nosed based on results of blood tests with low thyroid
hormone levels in the presence of high serum Thyroid
Stimulating Hormone (TSH) concentrations (usually >
4.0 mU/L). Treatment with the synthetic form of thyrox-
ine (Levothyroxine or LT4) is the treatment of choice in
these patients and patients are generally managed in pri-
mary care. LT4 is prescribed to 3–4 % of the general
population and its use is increasing [3–5]. Thyroid func-
tion changes with age and several reports suggest that
the upper limit of the TSH reference range increases
with age [6–10]. In addition, observational studies have
shown that older individuals with a slightly raised serum
TSH level have no adverse consequences [11–16]. In
fact, one report suggests that a slightly raised TSH may
be beneficial for survival in 85-year old individuals
followed up for four years [17]. Despite this, all patients
are treated uniformly with the aim of achieving a serum
TSH target level (usually 0.4–4.0 mU/L) and age-specific
ranges are not used. Moreover, evidence obtained from
General Practice records suggests LT4 is increasingly
being prescribed for older individuals and for minimally
raised serum TSH levels [18]. This issue is of increasing
importance as the populations in most developed – and
many developing – countries are ageing and diagnoses
of hypothyroidism are therefore likely to rise. Before a
definitive randomised controlled trial (RCT) in the older
hypothyroid population can be conducted it would be
highly desirable to assess its feasibility. We, therefore,
designed a feasibility RCT to investigate lower dose LT4
(aiming for a higher than usual serum TSH) versus usual
dose LT4 (aiming for the currently utilised serum TSH
range) in hypothyroid individuals aged 80 years or more.
We report the feasibility of this trial in this paper.
Methods
The detailed protocol has been published previously
[19]. Briefly, a dual-centre single-blind RCT of elderly
(≥80 years) individuals with primary hypothyroidism and
good biochemical control (as demonstrated by serum
TSH levels within the reference range in the preceding
3 months) was organised. After providing written in-
formed consent, participants were randomised in a 1:1
ratio to either usual dose LT4 (aiming to continue to
keep serum TSH between 0.4 and 4.0 mU/L) or lower
dose LT4 (reduced by 25 mcg daily initially and a further
25 mcg daily, if required at 12 weeks) to aim for a
slightly higher serum TSH level of 4.1–8.0 mU/L. After
randomisation participants were assessed at 12 and
24 weeks, with a final follow-up phone call at 25 weeks.
The inclusion criteria required participants of either
gender, aged 80 years or older, living independently in
the community, who had been prescribed LT4 (at least
50 mcg daily) for at least 6 months and whose serum
TSH was between 0.4 and 4.0 mU/L in the preceding
3 months. Patients were excluded if they were deemed
to not have capacity to provide written informed con-
sent, had severe chronic medical conditions that would
prevent participation, thyroid cancer, on medications
affecting thyroid function, non-English speakers, had
participated in another RCT in the previous 3 months
or had lactose intolerance.
The primary objectives were to demonstrate that
recruitment to such a trial is possible; to gauge partici-
pants’ acceptability of being part of the study; to assess
the length of time required to complete recruitment; to
assess the dose titration strategy and the length of time
required to achieve desired TSH levels; and to gauge
medication compliance.
The design and analysis followed published recom-
mendations for feasibility studies [20, 21]. As such, no
formal sample size calculation was performed; a target
sample size of 50 randomised participants was deemed
sufficient to assess the feasibility of the trial. The data ana-
lyses were descriptive, and statistical comparisons between
randomised treatment groups were not undertaken.
Results
Screening and recruitment
Participants were screened for their eligibility to partici-
pate in the trial via one of three possible routes: from
participating GP practices, hospital endocrine clinics or
self-referral responding to posters in hospitals and
participating GP practices. (See Fig. 1)
Twenty research-active practices agreed to identify
potential patients for the trial. These GP practices were
identified by the then National Institute for Health
Research, Primary Care Research Network. Of these, two
practices did not have the capacity to identify patients
for the study and a third responded late in the recruit-
ment process. The remaining 17 GP practices facilitated
the identification of potential participants and posted
letters of invitation (Table 1). The prevalence of treated
hypothyroid patients aged ≥ 80 years ranged from 0.5 to
1.4 % of the total number of patients registered in those
practices (Table 1). A total of 377 invitation letters (with
a reply slip and stamped addressed envelope) were sent
by practice staff and 233/377 (62 %) responded, of which
66 (18 % of total invitations) agreed to participate. The
protocol allowed the participating GP practices to send
reminder letters to patients that had not replied but this
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was not followed. Subsequently, 11 individuals changed
their mind and declined participation. The reasons given
for changing their mind related to either not under-
standing the study requirements or due to change in cir-
cumstances (such as illness). A further 9 patients were
deemed ineligible after study-specific screening as ei-
ther their serum TSH was too low (n = 6) or too high
(n = 3). Therefore, a total of 46 patients (12 % of the
377 potentially eligible participants) were randomised
via this route.
Another 13 participants were invited by either the
study team or self referred in response to publicity
posters in hospitals, the NIHR portfolio or via the
patient-led charity the British Thyroid Foundation news-
letter. Of these, 2 (15 %) participants were screened and
subsequently randomised.
Randomisation process
Participants were randomised in a ratio of 1:1, using ran-
dom permuted blocks. Randomisation was stratified by
usual (pre-study) LT4 dose (50, 75, 100 and 125 mcg
daily) and administered by the Newcastle Clinical Trials
Unit using a secure password-protected web-based
system (Table 2).
Baseline characteristics
The median age of the participants was 83 years (range:
80 to 93 years) and majority (71 %) were women (Table 3).
Primary outcome measures
This feasibility trial had five primary outcome measures.
1. Participants’ willingness to enter the trial (as gauged
by the ratio of those who consented to participate to
those who were potentially eligible and approached):
57 out of 390 (15 %) potentially eligible patients
consented to participate but, as stated above, 9
individuals (16 % of the potentially eligible group)
were not eligible due to abnormal thyroid function
at screening.
Fig. 1 Recruitment summary
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2. Participants’ acceptability of study design (as
measured by the completion rate of participants in
each randomised group): 21 out of 24 (87.5 %) and
19/24 (79.2 %) randomised participants completed
the trial in the usual and higher TSH arms,
respectively.
3. Participant recruitment rate (as measured by the
number of patients randomised divided by the
length of the recruitment period): Participants were
recruited between 17th October 2012 and 10th July
2013 with the first participant randomised on 9th
November 2012 and the last one on 10th July 2013.
The projected recruitment was 5 or 6 participants/
month. Over the 267 days that trial recruitment was
open 48 participants were recruited (5.5
participants/month) (See Fig. 2).
4. Dose titration strategy and length of time required
to achieve desired TSH levels (as calculated by
number of participants in each group that reach
target TSH range at both 12 and 24 weeks): For the
40 participants who remained in the study until
their final study assessment, most participants in the
usual dose arm stayed within their target TSH range
of 0.4–4.0 mU/L whereas half of the higher target
TSH arm achieved their target TSH range (Table 4).
5. Medication compliance (tablet count at each visit):
At the end of visits 2 and 3, participants were asked
to return any surplus study drug in the original
packaging to the study team, who verified and
documented compliance. Compliance was deemed
to be generally good. In participants who completed
the trial, n = 40, compliance was 100 and 95 % at
Table 1 Number of participants approached and randomised by each GP practice
Practices a Total registered
patients (n) (A)
Potentially eligible hypothyroid
patients aged≥ 80 year (% of A)
Invites sent c (n) (B) Replies received
(% of B)
Consented to be
screened (n) (% of B)
Randomised
(n) (% of B)
A 16,340 112 (0.7 %) 112 63 (56 %) 20 (18 %) 13 (12 %)
B 5475 42 (0.8 %) 42 25 (60 %) 6 (14 %) 6 (14 %)
C 8830 75 (0.9 %) 14 14 (100 %) 7 (50 %) 5 (36 %)
D 9230 58 (0.6 %) 39 23 (59 %) 5 (13 %) 3 (8 %)
E 11,019 63 (0.6 %) 20 15 (75 %) 3 (15 %) 3 (15 %)
F 10,141 28 b 11 10 (91 %) 4 (36 %) 3 (30 %)
G 5960 82 (1.4 %) 20 14 (70 %) 4 (20 %) 3 (15 %)
H 6875 52 (0.8 %) 10 6 (50 %) 3 (30 %) 3 (30 %)
I 4478 57 (1.3 %) 4 4 (100 %) 2 (50 %) 2 (50 %)
J 7460 36 (0.5 %) 36 20 (50 %) 6 (17 %) 1 (3 %)
K 3728 7 b 7 4 (57 %) 1 (14 %) 1 (14 %)
L 11,788 31 b 20 14 (70 %) 1 (5 %) 1 (5 %)
M 6893 9 b 9 3 (33 %) 1 (11 %) 1 (11 %)
N 19,223 20 b 10 7 (70 %) 1 (10 %) 1 (10 %)
O 3274 3 b 3 1 (33 %) 1 (33 %) 0 (0 %)
P 3296 12 b 5 2 (40 %) 1 (20 %) 0 (0 %)
Q 5565 15 b 15 8 (53 %) 0 (0 %) 0 (0 %)
Total 139,575 703 377 233 (62 %) 66 (18 %) 46 (12 %)
aThe names of the GP practices are not shown to protect identity
bFor these practices the total number of potentially eligible patients was not provided
cSome practices were asked to only send invites to a random selection of patients to be able to obtain a wide spread of responses from GP practices as possible
Table 2 Distribution of patients by randomisation strata (pre-study dose of Levothyroxine) and allocated treatment group
Pre-study dose
of Levothyroxine
Treatment group Total
randomisedTarget TSH range 0.4–4.0 mU/L Target TSH range 4.1–8.0 mU/L
50 μg daily 5 5 10
75 μg daily 9 9 18
100 μg daily 8 7 15
125 or more μg daily 2 3 5
Total 24 24 48
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both visits in the usual TSH and higher target TSH
arms, respectively (Table 4).
Adverse Events (AEs) and Serious Adverse Events
(SAEs): There were 119 AEs reported by 37 patients; 16
patients in the usual TSH arm reporting 49 AEs (mean
= 3.1 per patient, sd = 2.1) and 21 patients in the higher
TSH arm reporting 70 AEs (mean = 3.3, sd = 2.2).
Patients reported between 1 and 10 AEs over the course
of the study. The frequency of AEs with regards to the
various organ-systems appeared to be broadly similar.
For example, the frequency of participants reporting
new-onset or worsening tiredness/fatigue was 41.7 % vs
50 % in the usual and higher TSH arms, respectively.
Muscle aches and pains (29.2 % vs 16.7 %), dizziness
(20.8 % vs 25 %) and constipation (16.7 % vs 29.2 %)
were comparable in the two groups.
There were three SAEs, two in the usual TSH arm and
one in the higher TSH arm. (See Table 5 for details).
Site of follow-up: At baseline 71 % of patients (34/48)
chose to have their first study visit at home and 29 %
(14/48) chose to come into hospital out-patients. At visit
2, four patients switched from out-patient visits to home
visits with one patient switching in the other direction
(this patient had become a hospital inpatient). Of the 40
patients still in the study at visit 3, 80 % (32/40) had
their visit at home and 20 % (8/40) had their visit as an
out-patient.
Phone contacts: Over the course of the 24 week study
period a total of 27 telephone contacts were made by 20
participants and discussed with the research staff. The
majority (20/27) were made in the first 12 weeks; of
which 15 were in the first 4 weeks. The queries were
with regards to new or existing symptoms (20 contacts
by 14 participants; n = 8 in usual TSH arm and n = 6 in
higher TSH arm), query relating to study drug (4 phone
calls by 3 participants, all in usual TSH arm), and one
phone call each for taking study drug in addition to
usual dose levothyroxine (usual TSH arm) and problems
in swallowing study drug (usual TSH arm).
Withdrawals and reasons: Eight patients withdrew
from the study; three from the usual TSH arm and five
from the higher TSH arm (Table 6). Five patients with-
drew before visit 2 (two usual TSH, three higher TSH),
one patient withdrew at visit 2 (higher TSH arm), and
two patients withdrew after visit 2 but before visit 3 (one
usual TSH and 1 higher TSH arm, respectively). Three
of the five participants withdrew (60 %) from the site
that required a visit to a Research Facility whereas only
5/43 participants (12 %) withdrew from the site that
offered home visits. In seven participants, the reasons
cited for withdrawal were AEs (mainly tiredness or
constipation in six and infected foot and wrist pain in a
seventh). One participant was withdrawn from the study
by the research team for safety reasons as she was found
to be taking the study drug in addition to her usual
levothyroxine medication.
Discussion
It is currently unclear what the best practice for man-
aging hypothyroidism is in older people. There is good
evidence that thyroid hormone requirements change
with age and that the current practice of treating every-
one in a uniform fashion may not be appropriate. This
feasibility RCT has demonstrated that reducing the dose
of the synthetic thyroid hormone levothyroxine is
possible and that patients are willing to participate.
Table 3 Baseline characteristics
Total
n =48
Sex
Female (n,% of females) 34 (71 %)
Male (n, % of males) 14 (29 %)
Age (years) Median (range) 83.0 (80.0 − 93.0)
Blood pressure (mmHg) Median (IQR)
Systolic 154.5 (141.0 − 168.5)
Diastolic 85.0 (77.0 − 92.5)
Physical examination Mean (sd)
Height (cm) 158.8 (8.8)
Weight (kg) 68.5 (13.1)
BMI (kg/m2) 27.1 (4.7)
Pulse (bpm) 67.9 (9.8)
Chronic conditions n (%)
Type 2 diabetes mellitus 4 (8.3)
Hypertension 24 (50)
Ischaemic heart disease 13 (27.1)
Cerebrovascular disease 7 (14.6)
COPD 6 (12.5)
Blood results Median (IQR)
TSH (mU/L) 1.43 (0.88 − 2.64)
FT4 (pmol/L) 18.8 (16.7 − 19.7)
FT3 (pmol/L) 3.8 (3.6 − 4.2)
Total Cholesterol (mmol/L) 4.9 (4.4 − 6.2)
HDLc (mmol/L) 1.6 (1.5 − 1.9)
Triglycerides (mmol/L) 1.3 (1.0 − 1.9)
Serum CTX (pg/mL) 0.27 (0.17 − 0.37)
TPO antibodies
< 35 IU/ml (n, %) 28 (58 %)
≥ 35 IU/ml (n, %) 20 (42 %)
IQR interquartile range, sd standard deviation, bpm beats per minute, COPD
chronic obstructive pulmonary disease, TSH thyroid stimulating hormone, FT4
free thyroxine, FT3 free triiodothyronine, HDLc high density lipoprotein
cholesterol, CTX carboxy-terminal collagen crosslinks, TPO thyroid peroxidase
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The population of the western world - including the
United Kingdom - is ageing. Ageing of the population
refers to both the increase in the median age as well as
the increase in the absolute number and proportion of
older individuals. The number of people aged 75 and
over has increased by 89 % over the period 1974 to 2014
and now makes up 8 % of the total population [22]. Be-
tween 2015 and 2020, when the general population is
expected to increase by 3 %, it is estimated that people
aged 65 years or more will rise by 12 % to 1.1 million;
those over 85 years by 18 % to 300,000; and the number
of centenarians by 40 % (7000) [22]. Similar demographic
changes are occurring across much of the Western world.
For instance, in the United States it is estimated that there
are now about six million persons aged 85 years and older
and this number may reach 19 million in 2050 [23]. Data
from this feasibility study suggests that the prevalence of
treated hypothyroidism in the over 80 age group is
between 0.5 and 1.4 % of the entire population. It is also
apparent that the majority of hypothyroid patients in this
age group are on modest doses of LT4 – which is indica-
tive that treatment was commenced for borderline raised
TSH levels. This has significant implications for the man-
agement of hundreds of thousands of older hypothyroid
individuals in the United Kingdom. Furthermore, as the
number of older individuals increases then the absolute
number of older people with treated hypothyroidism is
also likely to grow.
The result of this feasibility trial has shown that it is
possible to recruit participants into an interventional
trial to aim for a higher than usual target serum TSH.
The randomisation rate was approximately 5.5 partici-
pants per month from the 17 GP practices that identi-
fied patients and from the other sources of referral.
Overall, 12 % of potentially eligible patients consented to
participate and were randomised. This feasibility data
suggests that a large-scale RCT would have to recruit
from hundreds of GP practices. Furthermore, allowance
would have to be made for 16 % (possibly even higher in
a study of a longer duration) of participants to withdraw
from the study. Any subsequent full RCT would have to
be of longer duration (probably several years) and
designed to be able to answer the important question of
the optimum target serum TSH to aim for in older
hypothyroid patients. Such a trial would require hard
clinical end points including cardiovascular events and
fractures as its main outcome measures.
One of the limitations of this trial is that we are unable
to assess the characteristics of individuals who refused
to participate. This is because study invitations were sent
by individual GP practices and the responses were
received in an anonymised form by the study team.
Fig. 2 Plot of cumulative number of patients randomised, target versus actual
Table 4 Dose titration strategy and compliance with study medications
Dose titration strategy:
Participants who remained in the study until their final study
assessment (i.e. excluding withdrawals), n = 40
Usual TSH range (0.4–4.0 mU/L)
n = 21
Higher TSH range (4. 1–8.0 mU/L)
n = 19
Percent achieving target TSH range at week 12 (visit 2) 18/21 (85.7 %) 6/19 (31.6 %)
Percent achieving target TSH range at week 24 (visit 3) 18/21 (85.7 %) 10/19 (52.6 %)
Percent compliant at week 12 (visit 2) 21/21 (100 %) 18/19 (94.7 %)
Percent compliant at week 24 (visit 3) 21/21 (100 %) 18/19 (94.7 %)
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Therefore, it is not possible to assess differences between
responders and non-responders.
Adverse events and serious adverse events did appear
to be similar in both the usual TSH arm as well as the
higher TSH arm in our study. However, this feasibility
trial was not powered to detect a significant difference
in any effect size. It is therefore possible that there may
be a higher incidence of adverse events in a larger trial
over a longer follow-up period. This would require
support to be available for study participants. In this trial
telephone support was made use of by a number of
participants and may have contributed to their retention.
The telephone contacts were made mostly in the first
few weeks after randomisation and related to either
symptoms or study drug. It is important to consider pro-
viding telephone support in a full large RCT particularly
in the first 4 weeks after commencing study drug. In
addition, it is also evident that participants in this age
group prefer to have home visits rather than to have to
come to a hospital research facility. It is unclear how
participants would view visits to their local GP practice.
It is important to consider strategies that would help
retain participants in the trial and lead to high comple-
tion rates. Approximately 4 out of 5 randomised partici-
pants completed this trial. This was achieved by offering
flexible study dates, times and venue, providing alterna-
tive appointments at short notice, being seen by the
same member of staff at each visit and availability of
telephonic support.
This feasibility trial revealed that of the patients rando-
mised to a higher TSH range, who remained in the study
until their final study assessment, only half reach their
target. This is not surprising given that up to half the
hypothyroid population, irrespective of age does not
Table 5 Chronological listing of serious adverse events
Treatment
allocation
Randomisation date Date of initial
report
Description Onset Date Severity SAE reason Outcome
Usual TSH arm 01/03/2013 26/04/2013 Stroke 22/04/2013 mild Involved patient
hospitalisation
Recovered with
sequelae
Usual TSH arm 20/03/2013 13/06/2013 Possible overdose on
levothyroxine
12/06/2013 mild Other significant
medical event
Completely recovered
Higher TSH arm 21/01/2013 01/07/2013 Cardiac arrest due to acute
myocardial infarction
25/06/2013 severe Life threatening Death (after study
completion: 05/08/2013)
Table 6 Chronological listing of withdrawals
Subject ID Treatment
allocation
Randomisation
date
Withdrawal date Days in the
study
Reason (severity and relation to study drug)
709 Reduced dose 07/12/2012 09/01/2013 34 Withdrew due to AEs experienced whilst on the study: constipation,
tiredness and generally unwell (mild, possibly related)
103 Usual dose 11/01/2013 23/01/2013 13 Withdrew due to “feeling unwell” (mild, possibly related)
104 Reduced dose 11/01/2013 27/03/2013 76 Withdrew due to infected right foot (moderate, not related), loose
stools (moderate, unknown relationship to study drug) and sore
wrist (mild, unknown relationship to study drug)
509 Reduced dose 26/11/2012 22/04/2013 148 6 weeks after Visit 2 withdrew from the study due to tiredness
(moderate, possibly related)
205 Usual dose 01/03/2013 22/04/2013 53 Withdrew due to fatigue which started 2 weeks after commencing
the study drug. The patient was hospitalised with a mild stroke on
22/04/13, reported to be linked to ongoing hypertension (severe,
not related).
515 Reduced dose 18/02/2013 08/05/2013 80 Withdrew after experiencing several AEs: dry skin, dry hair, feeling
cold, weight gain and tiredness (mild, possibly related), and swollen
face with itching (mild, not related) - unscheduled home visit: thyroid
function normal, weight gain of 0.3kgs.
521 Reduced dose 15/05/2013 12/06/2013 29 Withdrew after experiencing several AEs: nausea and loss of appetite
(mild, not related), vertigo (mild, not related) and confusion (mild,
not related)
614 Usual dose 20/03/2013 27/06/2013 100 At Visit 2 patient reported that she had been taking her prescribed
dose of LT4 as well as the study medication. Patient reported no AEs.
Serum thyroid function was normal (TSH 0.60, FT4 20.8). Subsequently
the patient changed her mind and withdrew.
AEs adverse events, LT4 levothyroxine
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have good biochemical control as evidenced by their
serum TSH level [24, 25]. The implications of this are
that more frequent or smaller dose adjustments of
levothyroxine may be required in the full trial to be able
to achieve a higher proportion of participants in the
desired relaxed TSH range.
Conclusion
In conclusion, this feasibility trial has shown that it is
possible to recruit and retain patients with levothyroxine
treated hypothyroidism aged 80 years or older into a RCT.
Several important lessons have been learnt that would
help to design a trial that should be able to successfully
recruit and retain patients into a longer-term study.
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